Please Wait.....
Report
Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028
Market Report I 2023-11-23 I 263 Pages I MarketsandMarkets
The global continuous bioprocessing market is projected to reach USD 599 million by 2028 from USD 218 million in 2023, at a CAGR of 22.4% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing adoption of continuous bioprocessing among CDMOs and CMOs. Continuous bioprocessing is becoming more popular among CDMOs and CMOs for the production of biopharmaceuticals. These organizations face increasing pressure to manufacture biopharmaceuticals faster and more efficiently, and continuous bioprocessing can help them meet this demand. Additionally, continuous bioprocessing is moving into larger-scale projects and new therapeutic areas. This trend is expected to drive the growth of the continuous bioprocessing market in the coming years.
"The monoclonal antibodies segment accounted for the largest share by application in 2022."
In 2022, the monoclonal antibodies segment accounted for the largest share by application in the global continuous bioprocessing market. Continuous bioprocessing is rapidly gaining momentum in monoclonal antibody bioprocessing, providing potential advantages such as smaller facility footprints, lower investment costs, flexibility, and process economy. The commercial success of mammalian cell-derived mAbs has led to the increased demand for novel single-use bioreactor systems that provide greater productivity & flexibility and reduce costs.
"The US has continued to dominate the continuous bioprocessing market during the forecast period of 2023-2028."
The US dominated the continuous bioprocessing market in North America in 2022. The US is the dominant market for biopharmaceuticals, accounting for around a third of the global market. It is the world leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US pharmaceutical firms hold the intellectual property rights for most new medicines and conduct over half the world's R&D in pharmaceuticals. Bioprocessing companies in the US are actively participating in the development of biopharmaceuticals using continuous bioprocessing. These companies are also widely offer perfusion-based products, which offer less turnaround time and are energy-efficient. These factors are supporting the growth of the continuous bioprocessing market in the country.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Sartorius AG (Germany)
- Thermo Fisher Scientific Inc. (US)
- Repligen Corporation (US)
- Merck KGaA (Germany)
- 3M Company (US)
- Getinge AB (Sweden)
- Eppendorf SE (Germany)
- Corning Incorporated (US)
- Entegris (US)
- FUJIFILM Holdings Corporation (Japan)
- Meissner filtration products, Inc. (US)
- Kuhner AG (Switzerland)
- Esco Lifesciences Group (Singapore)
- SATAKE MultiMix Corporation (Japan)
- Bionet (Spain)
- Stobbe Group (Switzerland)
- bbi-biotech GmbH (Germany)
- OmniBRx Biotechnologies (India)
- Cell Culture Company, LLC (US)
- Pierre Guerin (France)
- Solida Biotech GmbH (Germany)
- Zellwerk GmbH (Germany)
- 3D Biotek, LLC (US)
- FiberCell Systems Inc. (US)
Research Coverage:
This research report categorizes the continuous bioprocessing market by product (chromatography systems and consumables, filtration systems and devices, bioreactors, cell culture media, cell lines, buffers and reagents, and other products), by scale of operation (commercial operations and clinical operations), by process (downstream bioprocess and upstream bioprocess), by application (monoclonal antibodies, vaccines, cell and gene therapy, and other applications), by end users (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the continuous bioprocessing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the continuous bioprocessing market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall continuous bioprocessing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising demand for biopharmaceuticals, growing adoption among CDMOs and CMOs, advantages of continuous bioprocessing over batch/fed-batch mode, favorable regulatory & government support for innovative technologies, and emergence of integrated end-to-end continuous bioprocessing), restraints (high capital investment to limit entry for small players and stringent regulatory requirements), opportunities (high growth potential of emerging economies and PAT-enabled optimization of continuous bioprocessing), and Challenges (integration into existing manufacturing facilities and operational challenges) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the continuous bioprocessing market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the continuous bioprocessing market
- Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kuhner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), and among others in the market.
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS AND EXCLUSIONS 37
1.3 MARKET SEGMENTATION 38
FIGURE 1 CONTINUOUS BIOPROCESSING MARKET SEGMENTATION 38
1.4 YEARS CONSIDERED 38
1.5 CURRENCY CONSIDERED 39
1.6 LIMITATIONS 39
1.7 STAKEHOLDERS 39
1.8 RECESSION IMPACT 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 2 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 42
2.1.2 PRIMARY DATA 43
FIGURE 3 CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES 43
2.2 MARKET SIZE ESTIMATION 44
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022) 44
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS) 45
FIGURE 6 ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022) 45
2.2.1 INSIGHTS FROM PRIMARIES 46
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 46
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 47
2.3 GROWTH FORECAST 48
FIGURE 9 CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023-2028) 48
FIGURE 10 CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
2.4 DATA TRIANGULATION & MARKET BREAKDOWN 50
FIGURE 11 DATA TRIANGULATION METHODOLOGY 50
2.5 RESEARCH ASSUMPTIONS 51
2.6 RISK ANALYSIS 51
2.7 RECESSION IMPACT ANALYSIS 51
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH) 51
TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION) 52
TABLE 3 US HEALTH EXPENDITURE, 2023-2030 (USD MILLION) 52
3 EXECUTIVE SUMMARY 53
FIGURE 12 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 53
FIGURE 13 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION) 54
FIGURE 14 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 54
FIGURE 15 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 55
FIGURE 16 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 56
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET 57
4 PREMIUM INSIGHTS 58
4.1 CONTINUOUS BIOPROCESSING MARKET OVERVIEW 58
FIGURE 18 RISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 58
4.2 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT 59
FIGURE 19 CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 59
4.3 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION 60
FIGURE 20 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 60
4.4 CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
FIGURE 22 CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
5.2 MARKET DYNAMICS 62
TABLE 4 CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS 62
5.2.1 DRIVERS 63
5.2.1.1 Rising demand for biopharmaceuticals 63
5.2.1.2 Growing adoption among CDMOs and CMOs 63
5.2.1.3 Advantages of continuous bioprocessing over batch/fed-batch mode 64
5.2.1.4 Favorable regulatory & government support for innovative technologies 65
5.2.1.5 Emergence of integrated end-to-end continuous bioprocessing 65
5.2.2 RESTRAINTS 66
5.2.2.1 High capital investments to limit entry for smaller players 66
5.2.2.2 Stringent regulatory requirements 66
5.2.3 OPPORTUNITIES 67
5.2.3.1 High growth potential of emerging economies 67
5.2.3.2 PAT-enabled optimization of continuous bioprocessing 68
5.2.4 CHALLENGES 68
5.2.4.1 Integration into existing manufacturing facilities 68
5.2.4.2 Operational challenges 69
5.3 PRICING ANALYSIS 70
TABLE 5 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022) 70
TABLE 6 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022) 70
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 71
FIGURE 23 REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS 71
5.5 VALUE CHAIN ANALYSIS 72
FIGURE 24 CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS 72
5.5.1 RESEARCH & PRODUCT DEVELOPMENT 72
5.5.2 RAW MATERIAL, MANUFACTURING, AND ASSEMBLY 73
5.5.3 DISTRIBUTION AND AFTER-SALES SERVICES 73
5.6 SUPPLY CHAIN ANALYSIS 74
FIGURE 25 CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS 74
5.7 ECOSYSTEM ANALYSIS 75
FIGURE 26 ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET 75
TABLE 7 CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM (SUPPLY/DEMAND SIDE) 75
5.8 PATENT ANALYSIS 77
FIGURE 27 PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING MARKET (JANUARY 2013-SEPTEMBER 2023) 77
5.9 KEY CONFERENCES AND EVENTS 78
TABLE 8 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023?2024) 78
5.10 REGULATORY LANDSCAPE 79
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.10.2 REGULATORY GUIDELINES 80
5.11 PORTER'S FIVE FORCES ANALYSIS 81
TABLE 13 CONTINUOUS BIOPROCESSING MARKET: PORTER'S FIVE FORCES ANALYSIS 81
5.11.1 THREAT OF NEW ENTRANTS 82
5.11.2 THREAT OF SUBSTITUTES 82
5.11.3 BARGAINING POWER OF SUPPLIERS 82
5.11.4 BARGAINING POWER OF BUYERS 82
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 82
5.12 TECHNOLOGY ANALYSIS 82
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 84
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS BIOPROCESSING PRODUCTS 84
5.14 KEY BUYING CRITERIA, BY END USER 85
FIGURE 29 KEY BUYING CRITERIA OF END USERS IN CONTINUOUS BIOPROCESSING MARKET 85
6 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT 86
6.1 INTRODUCTION 87
TABLE 14 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 87
6.2 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES 88
6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE MARKET 88
TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION) 88
TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 89
TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 89
TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 89
TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 90
TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION) 90
6.3 FILTRATION SYSTEMS AND DEVICES 90
6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO DRIVE MARKET 90
TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION) 91
TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 91
TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92
TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92
TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 92
TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION) 93
6.4 BIOREACTORS 93
6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND 93
TABLE 27 BIOREACTORS MARKET, BY REGION, 2021-2028 (USD MILLION) 94
TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94
TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 94
TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 95
TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 95
TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021-2028 (USD MILLION) 95
6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS 96
6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH 96
TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) 97
TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 97
TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 97
TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 98
TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 98
TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) 98
6.6 OTHER PRODUCTS 99
TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION) 100
TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 100
TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 100
TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 101
TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 101
TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION) 101
7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION 102
7.1 INTRODUCTION 103
TABLE 45 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 103
7.2 COMMERCIAL OPERATIONS 103
7.2.1 GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET 103
TABLE 46 CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION) 104
TABLE 47 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 104
TABLE 48 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 105
TABLE 49 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 105
TABLE 50 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 105
TABLE 51 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION) 106
7.3 CLINICAL OPERATIONS 106
7.3.1 INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET 106
TABLE 52 CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION) 107
TABLE 53 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 107
TABLE 54 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 107
TABLE 55 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 108
TABLE 56 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 108
TABLE 57 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION) 108
8 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS 109
8.1 INTRODUCTION 110
TABLE 58 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 110
8.2 DOWNSTREAM BIOPROCESS 110
8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET 110
TABLE 59 CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION) 111
TABLE 60 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 111
TABLE 61 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 112
TABLE 62 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 112
TABLE 63 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 112
TABLE 64 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION) 113
8.3 UPSTREAM BIOPROCESS 113
8.3.1 ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH 113
TABLE 65 CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION) 114
TABLE 66 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 114
TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 114
TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 115
TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION) 115
TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION) 115
9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION 116
9.1 INTRODUCTION 117
TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 117
9.2 MONOCLONAL ANTIBODIES 117
9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET 117
TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION) 118
TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) 118
TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) 119
TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) 119
TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) 119
TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION) 120
9.3 VACCINES 120
9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET 120
TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION) 121
TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 121
TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 121
TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 122
TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION) 122
TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION) 122
9.4 CELL & GENE THERAPY 123
9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND 123
TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION) 123
TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 124
TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 124
TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 124
TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION) 125
TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION) 125
9.5 OTHER APPLICATIONS 125
TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 126
TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 126
TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 126
TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 127
TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 127
TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 127
10 CONTINUOUS BIOPROCESSING MARKET, BY END USER 128
10.1 INTRODUCTION 129
TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 129
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 129
10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET 129
TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) 130
TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 130
TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 131
TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 131
TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 131
TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) 132
10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) 132
10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET 132
TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION) 133
TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 133
TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 134
TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 134
TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 135
TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION) 135
10.4 ACADEMIC & RESEARCH INSTITUTES 135
10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH 135
TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 136
TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 136
TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 137
TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 137
TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 137
TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 138
11 CONTINUOUS BIOPROCESSING MARKET, BY REGION 139
11.1 INTRODUCTION 140
TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021-2028 (USD MILLION) 140
11.2 NORTH AMERICA 140
FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT 141
TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 142
TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 142
TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 142
TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 143
TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 143
TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 143
11.2.1 US 144
11.2.1.1 High biopharmaceutical R&D spending to drive market 144
TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 144
TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 145
TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 145
TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 145
TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 146
11.2.2 CANADA 146
11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to propel market 146
TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 147
TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 147
TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 147
TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 148
TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 148
11.2.3 NORTH AMERICA: RECESSION IMPACT 148
11.3 EUROPE 149
TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 149
TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 150
TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 150
TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 150
TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 151
TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 151
11.3.1 GERMANY 151
11.3.1.1 Increasing initiatives for life sciences research to boost demand 151
TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 152
TABLE 139 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 153
TABLE 140 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 153
TABLE 141 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 153
TABLE 142 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 154
11.3.2 UK 154
11.3.2.1 Favorable government support for biotech clusters to propel market 154
TABLE 143 UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 155
TABLE 144 UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 155
TABLE 145 UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 155
TABLE 146 UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 156
TABLE 147 UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 156
11.3.3 FRANCE 156
11.3.3.1 Rising demand for mAbs and biologics to drive market 156
TABLE 148 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 157
TABLE 149 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 157
TABLE 150 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 157
TABLE 151 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 158
TABLE 152 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 158
11.3.4 ITALY 158
11.3.4.1 Growth in pharma & biopharma industries to boost demand 158
TABLE 153 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 159
TABLE 154 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 159
TABLE 155 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 160
TABLE 156 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 160
TABLE 157 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 160
11.3.5 SPAIN 161
11.3.5.1 Increasing R&D funding by academic institutes to support market growth 161
TABLE 158 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 161
TABLE 159 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 162
TABLE 160 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 162
TABLE 161 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 162
TABLE 162 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 163
11.3.6 REST OF EUROPE 163
TABLE 163 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 164
TABLE 164 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 164
TABLE 165 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 164
TABLE 166 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 165
TABLE 167 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 165
11.3.7 EUROPE: RECESSION IMPACT 165
11.4 ASIA PACIFIC 166
FIGURE 31 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT 167
TABLE 168 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 168
TABLE 169 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 168
TABLE 170 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 169
TABLE 171 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 169
TABLE 172 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 169
TABLE 173 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 170
11.4.1 CHINA 170
11.4.1.1 Government support and rising private investments to drive market growth 170
TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 171
TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 171
TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 171
TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 172
TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 172
11.4.2 JAPAN 172
11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support market growth 172
TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 173
TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 174
TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 174
TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 174
TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 175
11.4.3 INDIA 175
11.4.3.1 Growth in pharmaceutical industry to boost demand 175
TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 176
TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 176
TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 176
TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 177
TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 177
11.4.4 SOUTH KOREA 177
11.4.4.1 Rising focus on quality manufacturing practices to drive market 177
TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 178
TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 179
TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 179
TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 179
TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 180
11.4.5 REST OF ASIA PACIFIC 180
TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 181
TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 181
TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 181
TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 182
TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 182
11.4.6 ASIA PACIFIC: RECESSION IMPACT 182
11.5 LATIN AMERICA 183
TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 183
TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 184
TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 184
TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 184
TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 185
TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 185
11.5.1 BRAZIL 185
11.5.1.1 Rising focus on cell & therapy manufacturing to support market 185
TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 186
TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 186
TABLE 207 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 186
TABLE 208 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 187
TABLE 209 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 187
11.5.2 MEXICO 187
11.5.2.1 Increasing expansion of pharmaceutical companies to support market growth 187
TABLE 210 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 188
TABLE 211 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 188
TABLE 212 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 188
TABLE 213 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 189
TABLE 214 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 189
11.5.3 REST OF LATIN AMERICA 189
TABLE 215 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 190
TABLE 216 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 190
TABLE 217 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 190
TABLE 218 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 191
TABLE 219 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 191
11.5.4 LATIN AMERICA: RECESSION IMPACT 191
11.6 MIDDLE EAST & AFRICA 192
TABLE 220 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021-2028 (USD MILLION) 192
TABLE 221 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 192
TABLE 222 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 193
TABLE 223 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 193
TABLE 224 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 193
TABLE 225 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 194
11.6.1 MIDDLE EAST 194
11.6.1.1 Increasing demand for biopharmaceutical drugs to drive market 194
TABLE 226 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 195
TABLE 227 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 195
TABLE 228 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 195
TABLE 229 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 196
TABLE 230 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 196
11.6.2 AFRICA 196
11.6.2.1 Favorable initiatives for R&D investments to support market growth 196
TABLE 231 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 197
TABLE 232 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION) 197
TABLE 233 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION) 197
TABLE 234 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 198
TABLE 235 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION) 198
11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT 198
12 COMPETITIVE LANDSCAPE 199
12.1 OVERVIEW 199
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 199
12.3 REVENUE SHARE ANALYSIS 200
FIGURE 32 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2018?2022) 200
12.4 MARKET SHARE ANALYSIS 200
FIGURE 33 CONTINUOUS BIOPROCESSING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 201
TABLE 236 CONTINUOUS BIOPROCESSING MARKET: INTENSITY OF COMPETITIVE RIVALRY 201
12.5 COMPANY EVALUATION MATRIX 202
12.5.1 STARS 203
12.5.2 PERVASIVE PLAYERS 203
12.5.3 EMERGING LEADERS 203
12.5.4 PARTICIPANTS 203
FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 204
12.5.5 COMPANY FOOTPRINT ANALYSIS 205
TABLE 237 CONTINUOUS BIOPROCESSING MARKET: OVERALL COMPANY FOOTPRINT (2022) 205
12.5.6 PRODUCT FOOTPRINT OF COMPANIES 206
TABLE 238 CONTINUOUS BIOPROCESSING MARKET: PRODUCT FOOTPRINT ANALYSIS 206
12.5.7 REGIONAL FOOTPRINT OF COMPANIES 207
TABLE 239 CONTINUOUS BIOPROCESSING MARKET: REGIONAL FOOTPRINT ANALYSIS 207
12.6 START-UP/SME EVALUATION MATRIX 208
12.6.1 PROGRESSIVE COMPANIES 208
12.6.2 RESPONSIVE COMPANIES 208
12.6.3 DYNAMIC COMPANIES 209
12.6.4 STARTING BLOCKS 209
FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UP/SMES (2022) 209
12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SMES 210
TABLE 240 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 210
TABLE 241 CONTINUOUS BIOPROCESSING MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES 211
12.7 COMPETITIVE SCENARIOS AND TRENDS 212
12.7.1 PRODUCT LAUNCHES 212
TABLE 242 CONTINUOUS BIOPROCESSING MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020?OCTOBER 2023) 212
12.7.2 DEALS 212
TABLE 243 CONTINUOUS BIOPROCESSING MARKET: DEALS (JANUARY 2020?OCTOBER 2023) 212
12.7.3 OTHER DEVELOPMENTS 213
TABLE 244 CONTINUOUS BIOPROCESSING MARKET: OTHER DEVELOPMENTS (JANUARY 2020?OCTOBER 2023) 213
13 COMPANY PROFILES 214
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
13.1 KEY PLAYERS 214
13.1.1 DANAHER CORPORATION 214
TABLE 245 DANAHER CORPORATION: BUSINESS OVERVIEW 214
FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 215
13.1.2 SARTORIUS AG 218
TABLE 246 SARTORIUS AG: BUSINESS OVERVIEW 218
FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2022) 219
13.1.3 THERMO FISHER SCIENTIFIC INC. 223
TABLE 247 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 223
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 224
13.1.4 REPLIGEN CORPORATION 227
TABLE 248 REPLIGEN CORPORATION: BUSINESS OVERVIEW 227
FIGURE 39 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2022) 228
13.1.5 MERCK KGAA 231
TABLE 249 MERCK KGAA: BUSINESS OVERVIEW 231
FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022) 232
13.1.6 3M COMPANY 235
TABLE 250 3M COMPANY: BUSINESS OVERVIEW 235
FIGURE 41 3M COMPANY: COMPANY SNAPSHOT (2022) 236
13.1.7 GETINGE AB 238
TABLE 251 GETINGE AB: BUSINESS OVERVIEW 238
FIGURE 42 GETINGE AB: COMPANY SNAPSHOT (2022) 239
13.1.8 EPPENDORF SE 241
TABLE 252 EPPENDORF SE: BUSINESS OVERVIEW 241
FIGURE 43 EPPENDORF SE: COMPANY SNAPSHOT (2022) 242
13.1.9 CORNING INCORPORATED 244
TABLE 253 CORNING INCORPORATED: BUSINESS OVERVIEW 244
FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2022) 245
13.1.10 ENTEGRIS 246
TABLE 254 ENTEGRIS: BUSINESS OVERVIEW 246
FIGURE 45 ENTEGRIS: COMPANY SNAPSHOT (2022) 247
13.1.11 FUJIFILM HOLDINGS CORPORATION 249
TABLE 255 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 249
FIGURE 46 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 250
13.1.12 MEISSNER FILTRATION PRODUCTS, INC. 252
TABLE 256 MEISSNER FILTRATION PRODUCTS, INC.: BUSINESS OVERVIEW 252
13.1.13 KUHNER AG 254
TABLE 257 KUHNER AG: BUSINESS OVERVIEW 254
13.1.14 ESCO LIFESCIENCES GROUP 256
TABLE 258 ESCO LIFESCIENCES GROUP: BUSINESS OVERVIEW 256
13.1.15 SATAKE MULTIMIX CORPORATION 257
TABLE 259 SATAKE MULTIMIX CORPORATION: BUSINESS OVERVIEW 257
13.2 OTHER PLAYERS 258
13.2.1 BIONET 258
13.2.2 STOBBE GROUP 259
13.2.3 BBI-BIOTECH GMBH 260
13.2.4 OMNIBRX BIOTECHNOLOGIES 260
13.2.5 CELL CULTURE COMPANY, LLC 261
13.2.6 PIERRE GUERIN 261
13.2.7 SOLIDA BIOTECH GMBH 262
13.2.8 ZELLWERK GMBH 262
13.2.9 3D BIOTEK, LLC 263
13.2.10 FIBERCELL SYSTEMS INC. 263
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
14 APPENDIX 264
14.1 DISCUSSION GUIDE 264
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 269
14.3 CUSTOMIZATION OPTIONS 271
14.4 RELATED REPORTS 271
14.5 AUTHOR DETAILS 273
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security